Global University Venturing

Osage University Partners has returned to back the cancer and inflammatory drug developer based on research from multiple universities.

WUSTL spinout Wugen has collected $172m in a series B round to progress its pipeline targeting several cancer indications.

The gene editing technology developer is the latest spinout emerging out of the lab of David Liu at Broad Institute.

Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.

The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

MIT’s battery technology spinout will collect $200m in a private investment in public equity financing and list on the New York Stock Exchange.

IP Group has returned for a series C round for the PNNL spinout, having already backed the series A and B rounds.

Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.

Daryush Ila, a 10-year tech transfer veteran at FSU, will assume the vice-president for innovation and research role at UWG.

Bow Capital has helped supply fresh funding for the equity-free capital provider to boost its expansion and broaden its product offering.

The precision oncology platform is based on research by Duke and Hubrecht Institute faculty and the cash will fund technology development and clinical studies.